Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.08.2019 | Case report

Anaplastic lymphoma kinase inhibitors

Drug resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

An 18-year-old woman experienced resistance to crizotinib, ceritinib, lorlatinib and alectinib during treatment of pulmonary inflammatory myofibroblastic sarcoma. …
Literatur
Zurück zum Zitat Parker BM, et al. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. Journal of Oncology Pharmacy Practice 25: 1226-1230, No. 5, 01 Jul 2019. Available from: URL: http://doi.org/10.1177/1078155218781944 -USA Parker BM, et al. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. Journal of Oncology Pharmacy Practice 25: 1226-1230, No. 5, 01 Jul 2019. Available from: URL: http://​doi.​org/​10.​1177/​1078155218781944​ -USA
Metadaten
Titel
Anaplastic lymphoma kinase inhibitors
Drug resistance: case report
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-65790-4

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Empagliflozin